Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.76 |
| ▸ | CA9 | Q16790 | 15/20 | 0.76 |
| ▸ | CA1 | P00915 | 15/20 | 0.76 |
| ▸ | CA12 | O43570 | 14/20 | 0.76 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 3/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069535 | 0.86 | PTPN7 (0.73) | CA2CA9CA1CA12PTPN7 | |
| SCHEMBL672116 | 0.86 | CA2 (1.00) | CA2CA9CA1CA12CYP1A2 | |
| SCHEMBL672754 | 0.84 | CA2 (1.00) | CA2CA9CA1CA12CYP1A2 | |
| SCHEMBL671474 | 0.84 | CA2 (1.00) | CA2CA9CA1CA12CYP1A2 | |
| SCHEMBL672848 | 0.83 | CA2 (1.00) | CA2CA9CA1CA12PTPN7 | |
| SCHEMBL9280164 | 0.83 | PTPN7 (1.00) | CA2CA9CA1CA12PTPN7 | |
| SCHEMBL13456177 | 0.82 | SOS1 (0.73) | CA2CA9CA1CA12PTPN7 | |
| SCHEMBL21796364 | 0.81 | PTPN7 (0.64) | CA2CA9CA1CA12PTPN7 | |
| SCHEMBL672763 | 0.81 | CA12 (1.00) | CA2CA9CA1CA12CYP1A2 | |
| SCHEMBL673796 | 0.80 | CA2 (1.00) | CA2CA9CA1CA12CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC. (CA) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA2 5/4885CA9 25/4885CA1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.